pharmaceuticals
Jump to
3447 Results Found
  • Ajanta Pharma Standalone March 2021 Net Sales at Rs 748.07 crore, up 33.42% Y-o-Y May 04, 2021 03:01 PM IST

    Ajanta Pharma Standalone March 2021 Net Sales at Rs 748.07 crore, up 33.42% Y-o-Y

  • Zenotech Labs Standalone March 2021 Net Sales at Rs 7.85 crore, up 47.86% Y-o-Y May 04, 2021 02:56 PM IST

    Zenotech Labs Standalone March 2021 Net Sales at Rs 7.85 crore, up 47.86% Y-o-Y

  • Guj Themis Standalone March 2021 Net Sales at Rs 23.30 crore, down 11.59% Y-o-Y May 04, 2021 02:53 PM IST

    Guj Themis Standalone March 2021 Net Sales at Rs 23.30 crore, down 11.59% Y-o-Y

  • RPG Life Standalone March 2021 Net Sales at Rs 92.76 crore, up 4.61% Y-o-Y May 04, 2021 02:52 PM IST

    RPG Life Standalone March 2021 Net Sales at Rs 92.76 crore, up 4.61% Y-o-Y

  • Astec Life Standalone March 2021 Net Sales at Rs 171.92 crore, down 4.59% Y-o-Y May 04, 2021 02:52 PM IST

    Astec Life Standalone March 2021 Net Sales at Rs 171.92 crore, down 4.59% Y-o-Y

  • Laurus Labs Consolidated March 2021 Net Sales at Rs 1,411.93 crore, up 68.26% Y-o-Y Apr 29, 2021 07:30 PM IST

    Laurus Labs Consolidated March 2021 Net Sales at Rs 1,411.93 crore, up 68.26% Y-o-Y

  • Laurus Labs Standalone March 2021 Net Sales at Rs 1,398.74 crore, up 68.68% Y-o-Y Apr 29, 2021 07:13 PM IST

    Laurus Labs Standalone March 2021 Net Sales at Rs 1,398.74 crore, up 68.68% Y-o-Y

  • Biocon Consolidated March 2021 Net Sales at Rs 1,838.70 crore, up 16.3% Y-o-Y Apr 29, 2021 12:03 PM IST

    Biocon Consolidated March 2021 Net Sales at Rs 1,838.70 crore, up 16.3% Y-o-Y

  • Sanofi India Standalone March 2021 Net Sales at Rs 725.10 crore, down 7.57% Y-o-Y Apr 29, 2021 11:30 AM IST

    Sanofi India Standalone March 2021 Net Sales at Rs 725.10 crore, down 7.57% Y-o-Y

  • Biocon Standalone March 2021 Net Sales at Rs 491.60 crore, up 1.91% Y-o-Y Apr 29, 2021 11:24 AM IST

    Biocon Standalone March 2021 Net Sales at Rs 491.60 crore, up 1.91% Y-o-Y

  • Gland Pharma Q4 PAT seen up 17.3% YoY to Rs. 229 cr: Sharekhan Apr 12, 2021 09:14 PM IST

    Gland Pharma Q4 PAT seen up 17.3% YoY to Rs. 229 cr: Sharekhan

    Net Sales are expected to increase by 30 percent Y-o-Y (down 3.9 percent Q-o-Q) to Rs. 825.8 crore, according to Sharekhan.

  • Solara Active Pharma Q4 PAT seen up 223.6% YoY to Rs. 57.6 cr: Sharekhan Apr 12, 2021 09:14 PM IST

    Solara Active Pharma Q4 PAT seen up 223.6% YoY to Rs. 57.6 cr: Sharekhan

    Net Sales are expected to increase by 35.4 percent Y-o-Y (down 5.8 percent Q-o-Q) to Rs. 401.9 crore, according to Sharekhan.

  • Shilpa Medicare Q4 PAT may dip 72.3% YoY to Rs. 9.6 cr: Sharekhan Apr 12, 2021 09:03 PM IST

    Shilpa Medicare Q4 PAT may dip 72.3% YoY to Rs. 9.6 cr: Sharekhan

    Net Sales are expected to decrease by 15 percent Y-o-Y (down 2.2 percent Q-o-Q) to Rs. 187 crore, according to Sharekhan.

  • Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan Apr 12, 2021 09:02 PM IST

    Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan

    Net Sales are expected to increase by 31 percent Y-o-Y (down 2.6 percent Q-o-Q) to Rs. 810.3 crore, according to Sharekhan.

  • Abbott India Q4 PAT seen up 55.7% YoY to Rs. 172.8 cr: Sharekhan Apr 12, 2021 09:02 PM IST

    Abbott India Q4 PAT seen up 55.7% YoY to Rs. 172.8 cr: Sharekhan

    Net Sales are expected to increase by 4 percent Y-o-Y (down 8.8 percent Q-o-Q) to Rs. 999.6 crore, according to Sharekhan.

  • Laurus Labs Q4 PAT seen up 366.3% YoY to Rs. 232.2 cr: Sharekhan Apr 12, 2021 09:02 PM IST

    Laurus Labs Q4 PAT seen up 366.3% YoY to Rs. 232.2 cr: Sharekhan

    Net Sales are expected to increase by 56.6 percent Y-o-Y (up 2 percent Q-o-Q) to Rs. 1,314.3 crore, according to Sharekhan.

  • Granules Q4 PAT seen up 253.6% YoY to Rs. 122.7 cr: Sharekhan Apr 12, 2021 09:02 PM IST

    Granules Q4 PAT seen up 253.6% YoY to Rs. 122.7 cr: Sharekhan

    Net Sales are expected to increase by 36.2 percent Y-o-Y (down 3.2 percent Q-o-Q) to Rs. 817.2 crore, according to Sharekhan.

  • Dr Reddy’s Lab Q4 PAT may dip 13.6% YoY to Rs. 674.5 cr: Sharekhan Apr 12, 2021 08:42 PM IST

    Dr Reddy’s Lab Q4 PAT may dip 13.6% YoY to Rs. 674.5 cr: Sharekhan

    Net Sales are expected to increase by 9 percent Y-o-Y (down 1.9 percent Q-o-Q) to Rs. 4,849.3 crore, according to Sharekhan.

  • Biocon Q4 PAT seen up 54.1% YoY to Rs. 203.4 cr: Sharekhan Apr 12, 2021 08:40 PM IST

    Biocon Q4 PAT seen up 54.1% YoY to Rs. 203.4 cr: Sharekhan

    Net Sales are expected to increase by 28.3 percent Y-o-Y (up 8 percent Q-o-Q) to Rs. 1,999.6 crore, according to Sharekhan.

  • Torrent Pharma Q4 PAT may dip 1.9% YoY to Rs. 308 cr: Sharekhan Apr 12, 2021 08:40 PM IST

    Torrent Pharma Q4 PAT may dip 1.9% YoY to Rs. 308 cr: Sharekhan

    Net Sales are expected to increase by 4.6 percent Y-o-Y (up 1.5 percent Q-o-Q) to Rs. 2,000.7 crore, according to Sharekhan.

  • Sun Pharma Q4 PAT seen up 82.2% YoY to Rs. 1,462.7 cr: Sharekhan Apr 12, 2021 08:40 PM IST

    Sun Pharma Q4 PAT seen up 82.2% YoY to Rs. 1,462.7 cr: Sharekhan

    Net Sales are expected to increase by 6.2 percent Y-o-Y (down 1.6 percent Q-o-Q) to Rs. 8,692.6 crore, according to Sharekhan.

  • LUPIN Q4 PAT seen up 3.5% YoY to Rs. 317.2 cr: Sharekhan Apr 12, 2021 08:40 PM IST

    LUPIN Q4 PAT seen up 3.5% YoY to Rs. 317.2 cr: Sharekhan

    Net Sales are expected to increase by 3.5 percent Y-o-Y (down 0.9 percent Q-o-Q) to Rs. 3,979 crore, according to Sharekhan.

  • IPCA Q4 PAT seen up 126.5% YoY to Rs. 194.8 cr: Sharekhan Apr 12, 2021 08:13 PM IST

    IPCA Q4 PAT seen up 126.5% YoY to Rs. 194.8 cr: Sharekhan

    Net Sales are expected to increase by 21.1 percent Y-o-Y (down 7.8 percent Q-o-Q) to Rs. 1,300 crore, according to Sharekhan.

  • Divis Q4 PAT seen up 41.1% YoY to Rs. 467.2 cr: Sharekhan Apr 12, 2021 08:12 PM IST

    Divis Q4 PAT seen up 41.1% YoY to Rs. 467.2 cr: Sharekhan

    Net Sales are expected to increase by 20.9 percent Y-o-Y (down 1.3 percent Q-o-Q) to Rs. 1,680 crore, according to Sharekhan.

  • Cipla Q4 PAT seen up 147.8% YoY to Rs. 609 cr: Sharekhan Apr 12, 2021 08:12 PM IST

    Cipla Q4 PAT seen up 147.8% YoY to Rs. 609 cr: Sharekhan

    Net Sales are expected to increase by 15 percent Y-o-Y (down 2.7 percent Q-o-Q) to Rs. 5,031.7 crore, according to Sharekhan.

Sections